



oncotype DX<sup>®</sup>  
Breast Cancer Assay



NEW

oncotype DX<sup>®</sup>  
Colon Cancer Assay

oncotype DX<sup>®</sup>  
Prostate Cancer Assay

The **3<sup>rd</sup>** update meeting on **Oncotype DX** assays

TEVA

ONCOTEST  
personalized medicine

Trust the Future<sup>®</sup>

28.6.2013  
The Peres Center for Peace  
132 Kedem St. Tel Aviv-Jaffa

28.6.2013 | The Peres Center for Peace, Jaffa

The **3<sup>rd</sup> update meeting**  
on **onco<sup>type</sup> DX** assays



The Peres Center for Peace  
132 Kedem St.  
Tel Aviv-Jaffa

**TEVA**

**ONCOTEST**  
personalized medicine

*Trust the Future<sup>®</sup>*

- 08:15 – 08:45 **Welcome and Reception**
- 08:45 – 08:50 **Opening Remarks**  
Lior Soussan-Gutman, Ph.D  
*Managing director Oncotest-TEVA*
- 08:50 – 09:10 **Delivering the Value of Precision Medicine to Physicians, Patients and Payors**  
Kim Popovits  
*Chairman of the Board, Chief Executive Officer and President, Genomic Health, Inc.*
- 09:10 – 09:45 **Therapeutic Implications of the Use of ODX in ER Positive, Node Positive Patients with Early Breast Cancer**  
Norman Walmark, MD  
*Chairman and Principal Investigator of the National Surgical Adjuvant Breast and Bowel Project (NSABP), Professor and Chairman of Human Oncology, Drexel University School of Medicine Philadelphia, Pennsylvania*
- 09:45 – 10:30 **DCIS: Making the Punishment Fit the Crime**  
William C. Wood, MD, FACS, FRCS (Hon) Eng, FRCS Glasg.  
*Distinguished Joseph Brown Whitehead Professor of Surgery, Division of Surgical Oncology, Department of Surgery, Emory University School of Medicine, Joint Professor of Global Health, Hubert Department of Global Health, Rollins School of Public Health*
- 10:30 – 11:30 **Brunch**
- 11:30 – 12:15 **Therapeutic Implications of the Use of Colon ODX in Stage II and III Disease**  
Norman Walmark, MD  
*Chairman and Principal Investigator of the National Surgical Adjuvant Breast and Bowel Project (NSABP), Professor and Chairman of Human Oncology, Drexel University School of Medicine Philadelphia, Pennsylvania*
- 12:15 – 13:00 **Refined Risk Assessment Leads to Refined Treatment for Prostate Cancer**  
Peter R. Carroll, MD, MPH  
*Professor and Chair, Ken and Donna Derr - Chevron Distinguished Professor Department of Urology, Associate Dean, Director of Clinical Services and Strategic Planning UCSF - Helen Diller Comprehensive Cancer Center University of California, San Francisco*



מרכז פרס לשלום